Hardback / bound
|
English
€89.50
- From €15,- no shipping costs.
- 30 days to change your mind and return physical products
Description
"This book provides a new outlook on avoiding the pandemics which have plagued mankind over the millennia."Peter JennerEmeritus Professor of Pharmacology, King's College London, UK"This seems to be a most impressive piece of work – the quantification, rigour and consistency of the arguments and data give it real power!"Robin IrvineEmeritus Royal Society Research Professor of Molecular Pharmacology at the University of Cambridge, UK"It reads very well; I think the central message is strongly given, that we should reduce the risk of pandemics through monitoring and maintaining the indoor air quality. I would be happy to recommend this book to everybody, whether they are students, homeowners, teachers, architects, building managers, or even UN/WHO technocrats."Peter RichardsonVice President of Pharmacology at Benevolent AI, UK
"This book provides a new outlook on avoiding the pandemics which have plagued mankind over the millennia."Peter JennerEmeritus Professor of Pharmacology, King's College London, UK"This seems to be a most impressive piece of work – the quantification, rigour and consistency of the arguments and data give it real power!"Robin IrvineEmeritus Royal Society Research Professor of Molecular Pharmacology at the University of Cambridge, UK"It reads very well; I think the central message is strongly given, that we should reduce the risk of pandemics through monitoring and maintaining the indoor air quality. I would be happy to recommend this book to everybody, whether they are students, homeowners, teachers, architects, building managers, or even UN/WHO technocrats."Peter RichardsonVice President of Pharmacology at Benevolent AI, UK
Hiroshi Kase, PhD, joined Kyowa Hakko Kogyo Co., Ltd. (Japan) in 1966, and served as researcher, as Director of the Pharmaceutical Research Institute and as Global Project Leader. As a representative accomplishment, he was involved in the discovery and development of adenosine A2A antagonist KW-6002 (istradefylline) for a new Parkinson's Disease drug with a novel action mechanism, leading to success in its launch in Japan and the United States. He is the author and editor of "Adenosine Receptor and Parkinson's Disease" (2000).Yoshikazu G. Mikawa, MD, PhD joined Dr Sydney Brenner's Molecular Genetics Unit in Cambridge, UK, in 1989 and collaborated in the USA until 2005. His work propelled DNA technologies, particularly in the next-generation sequencing. He developed a bacteriophage lambda peptide display system and genetically modified bacteria for ligand-receptor binding analysis. He was Principal Scientific Officer at Population Genetics Technologies Ltd, UK (2005-2013). He co-founded Nemesis Bioscience Ltd (UK) in 2014, focusing on cutting-edge technologies addressing antimicrobial resistance.
"This book provides a new outlook on avoiding the pandemics which have plagued mankind over the millennia."Peter JennerEmeritus Professor of Pharmacology, King's College London, UK"This seems to be a most impressive piece of work – the quantification, rigour and consistency of the arguments and data give it real power!"Robin IrvineEmeritus Royal Society Research Professor of Molecular Pharmacology at the University of Cambridge, UK"It reads very well; I think the central message is strongly given, that we should reduce the risk of pandemics through monitoring and maintaining the indoor air quality. I would be happy to recommend this book to everybody, whether they are students, homeowners, teachers, architects, building managers, or even UN/WHO technocrats."Peter RichardsonVice President of Pharmacology at Benevolent AI, UK
Hiroshi Kase, PhD, joined Kyowa Hakko Kogyo Co., Ltd. (Japan) in 1966, and served as researcher, as Director of the Pharmaceutical Research Institute and as Global Project Leader. As a representative accomplishment, he was involved in the discovery and development of adenosine A2A antagonist KW-6002 (istradefylline) for a new Parkinson's Disease drug with a novel action mechanism, leading to success in its launch in Japan and the United States. He is the author and editor of "Adenosine Receptor and Parkinson's Disease" (2000).Yoshikazu G. Mikawa, MD, PhD joined Dr Sydney Brenner's Molecular Genetics Unit in Cambridge, UK, in 1989 and collaborated in the USA until 2005. His work propelled DNA technologies, particularly in the next-generation sequencing. He developed a bacteriophage lambda peptide display system and genetically modified bacteria for ligand-receptor binding analysis. He was Principal Scientific Officer at Population Genetics Technologies Ltd, UK (2005-2013). He co-founded Nemesis Bioscience Ltd (UK) in 2014, focusing on cutting-edge technologies addressing antimicrobial resistance.